Cannabis Law Report

SEPTEMBER 13, 2021

(Nasdaq: MYMD) (“MyMD” or “the Company”), a clinical stage pharmaceutical company committed to extending healthy lifespan, today announced that it intends to initiate dosing for a Phase 2 trial of MYMD-1’s function in delaying aging early in the fourth quarter of 2021. For more information, visit www.mymd.com. in the blood.

Clinical Trials 52

Clinical Trials Pharmaceutical Research and Development Therapy 52

Cannabis Law Report

NOVEMBER 16, 2021

As cleared by the FDA, the primary endpoint of the Phase 2 double-blind, placebo-controlled clinical trial is to achieve a reduction in the circulating levels of tumor necrosis factor-alpha (TNF-?), For more information, visit www.mymd.com. tumor necrosis factor receptor I (TNFRI) and IL-6. MyMD Contact: Robert Schatz.

Pharmaceutical 52

Pharmaceutical Clinical Trials Research and Development Therapy 52

Cannabis Law Report

NOVEMBER 15, 2021

Although a limited number of CGTs are currently on the market, FDA officials predicted in 2019 that the agency will receive more than 200 investigational new drug applications per year for cell and gene therapies and that by 2025, it expects to have accelerated to 10 to 20 cell and gene therapy approvals per year 1. Join our mailing list.

Research and Development 52

Research and Development Therapy Clinical Trials Supply Chain 52

Cannabis Law Report

JANUARY 5, 2022

3 MyMD believes that there are no FDA-approved drugs for treating aging disorders and extending healthy lifespan in humans, a market expected to be at least $600 billion by 2025 according to a major investment bank. For more information, visit www.mymd.com. Cautionary Statement Regarding Forward-Looking Statements. 2 Goates et al.

Pharmaceutical 52

Pharmaceutical Clinical Trials Therapy Treatment 52

The Joint Blog

JULY 25, 2020

organic food market by 2025 is at $70.4 The agency maintains that they need more time to probe further into the science of cannabidiol, which will require thorough research and clinical trials before they can conclude certain products as GRAS. “To It has been predicted that the U.S CBD Products and the FDA The U.S.

CBD 33

CBD Clinical Trials Safety Media 33

Cannabis Law Report

DECEMBER 23, 2021

billion by 2025. The market sizing section provides forecasts on the estimated sales of the three most lucrative cannabinoid pharmaceuticals – from 2021-2025 – including Epidiolex, Sativex and Dronabinol. For more information about this report visit [link]. ResearchAndMarkets.com. Laura Wood, Senior Press Manager.

Pharmaceutical 96

Pharmaceutical Clinical Trials Research and Development Cannabinoids 96

SMPL

MAY 26, 2020

Miller spent the months after this meeting leading hundreds of CBD seminars for farmers; Dr. Kerr began informal patient surveys to track how CBD made people feel; and as he finished his book, Mr. Lee often traveled around with Mr. Laughter and Mr. Ringo’s high-CBD plants and seeds, spreading the gospel at pot shops across the West.

CBD 40

CBD Research and Development Pharmaceutical Seed-To-Sale 40